Hikma Pharmaceuticals PLC HIK-GB:London Stock Exchange

RT Quote | Exchange | GBp
Last | 09/30/22 BST
1,363.50quote price arrow up+14.00 (+1.04%)
52 week range
1,176.50 - 2,496.00
Loading...
  • Open1,351.50
  • Day High1,384.50
  • Day Low1,344.50
  • Prev Close1,349.50
  • 52 Week High2,496.00
  • 52 Week High Date11/04/21
  • 52 Week Low1,176.50
  • 52 Week Low Date09/23/22

Key Stats

  • Market Cap3,331.02M
  • Shares Out220.11M
  • 10 Day Average Volume1.51M
  • Dividend44.24
  • Dividend Yield3.24%
  • Beta0.17
  • YTD % Change-38.55

KEY STATS

  • Open1,351.50
  • Day High1,384.50
  • Day Low1,344.50
  • Prev Close1,349.50
  • 52 Week High2,496.00
  • 52 Week High Date11/04/21
  • 52 Week Low1,176.50
  • 52 Week Low Date09/23/22
  • Market Cap3,331.02M
  • Shares Out220.11M
  • 10 Day Average Volume1.51M
  • Dividend44.24
  • Dividend Yield3.24%
  • Beta0.17
  • YTD % Change-38.55

RATIOS/PROFITABILITY

  • EPS (TTM)124.10
  • P/E (TTM)10.99
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date08/18/2022
  • Div Amount16.5943
  • Split Date-
  • Split Factor-

Latest On Hikma Pharmaceuticals PLC

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
Hikma Pharmaceuticals Plc is a pharmaceutical company. The Company is focused on developing, manufacturing, marketing and selling of a broad range of generic, branded and in-licensed pharmaceuticals products in solid, semi-solid, liquid and injectable final dosage forms. The Company operates through three segments, such as Injectables, Generics and Branded. The Injectables business develops and manufactures generic injectable products, which are primarily used in hospitals....
Said Darwazah
Executive Chairman of the Board
Mazen Darwazah
Executive Vice Chairman of the Board, President of MENA
Khalid Nabilsi CPA
Chief Financial Officer
Majda Labadi
Executive Vice President - Organisational Development
Bassam Wael Rushdi Kanaan CPA
Executive Vice President - Corporate Development and M&A
Address
1 New Burlington Place
London
W1S 2HR
United Kingdom